SCGB2A1 and ovarian cancer: Of the 106 EOC specimens examined in this study, 42 (40%) cases were positive for MGB-2 immunoreactivity: 39 out of 84 (46%) primary ovarian cancers, and 3 out of 22 (14%) omental metastases.